Content about Company Technology

NEW YORK — SmartSource.com has gone mobile.

Thanks to Augme Technologies, the consumer coupon site now offers users the capability to scroll through available offers and select which coupons they want to use from any Web-enabled phone, smart phone or other mobile communications device, without the hassle of downloading special software or applications.

CHICAGO — Bolstered by a strong recent uptrend in sales and earnings and by clear signs that its massive realignment is beginning to bear real fruit, Walgreens’ top executives delivered an upbeat assessment of the company’s progress and its potential as a multichannel retail and healthcare powerhouse at the company’s annual shareholders’ meeting Wednesday.

BOTHELL, Wash. — Pfizer has paid Seattle Genetics $8 million to license its antibody technology, Seattle Genetics said Thursday.

Seattle Genetics, based in Bothell, Wash., said Pfizer would pursue antibodies for treating an unspecified form of cancer using its antibody-drug conjugate technology. ADCs are monoclonal antibodies that selectively deliver anti-cancer agents to tumor cells. Seattle Genetics has developed anti-tumor drugs called auristatins, which are attached to antibodies and then used to kill the cancer cells while sparing noncancer cells.

Supplier News — The Food and Drug Administration has approved a generic drug for hypertension made by Mylan. Mylan announced the approval of nifedipine extended-release tablets in the 30-mg, 60-mg and 90-mg strengths. The drug is a generic version of Bayer’s Adalat CC. Nifedipine tablets had sales of around $82 million during the 12-month period ended June 2010, according to IMS Health.



WESTON, Mass. and ZURICH — In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.

Among other assets, the agreement gives Biogen the worldwide rights to three preclinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system targets: alpha-synuclein, tau and TDP-43.

INDIANAPOLIS — One month after announcing it would acquire a leader in molecular imaging development, Eli Lilly announced it has completed its acquisition of Avid Radiopharmaceuticals.

BURLINGTON, Mass. — Palomar Medical Technologies, a researcher and developer of light-based systems for cosmetic treatments, has announced the launch of the first FDA-cleared, at-home laser designed to reduce fine lines and wrinkles around the eyes.

NOVI, Mich. — A coalition owned by 125 regional drug chains, independent pharmacies, regional drug wholesalers and specialty distributors will host its annual trade expo next month at the Hilton Orlando in Orlando, Fla.

The Chain Drug Marketing Association said it will celebrate its 85th year of uniting suppliers with its members, allowing buyers to discuss business opportunities with exhibitors, meet and exchange ideas with other buyers and learn about new CDMA programs that can help to increase profitability in the front end of their stores.

SAN DIEGO — As retail distribution for GreatCall's Jitterbug J cell phones expands, the company has placed a stronger emphasis on its health-and-wellness apps for the Jitterbug handsets.

NEW YORK — Consumers see smart phones as future personal, coupon-clipping shopper assistants, a global survey released Monday by Accenture found. According to the survey, 79% of smart-phone users would find it useful to download money-off coupons to their phones, and 73% of those shoppers would be receptive to being pinged with instant money-off coupons as they passed by an item in a store.

JERUSALEM — Oramed Pharmaceuticals, a developer of oral drug delivery solutions, has published an article in the Journal of Diabetes Science and Technology’s November issue describing evaluation of the company’s glucagon-like peptide (GLP-1) analog formulation (ORMD-0901) in regulating glucose excursions in animal models.